Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALNY

Alnylam Pharmaceuticals Inc

Sep 12 • 04:00PM ET

465.89

-2.69 -0.57 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO VUG VXF VOT IWP IBB CGGR IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	4.24%	Shs Outstand	130.98M	Perf Week	3.07%
Market Cap	61.07B	Forward P/E	78.95	EPS next Y	5.90	Insider Trans	-2.77%	Shs Float	125.52M	Perf Month	7.72%
Enterprise Value	60.95B	PEG	-	EPS next Q	0.28	Inst Own	97.90%	Short Float	3.17%	Perf Quarter	52.92%
Income	-319.09M	P/S	24.80	EPS this Y	146.91%	Inst Trans	2.04%	Short Ratio	3.56	Perf Half Y	92.72%
Sales	2.46B	P/B	243.51	EPS next Y	476.99%	ROA	-7.44%	Short Interest	3.97M	Perf YTD	97.99%
Book/sh	1.91	P/C	21.37	EPS next 5Y	-	ROE	-257.82%	52W High	484.21 -3.78%	Perf Year	81.84%
Cash/sh	21.80	P/FCF	-	EPS past 3/5Y	32.86% 23.11%	ROIC	-11.21%	52W Low	205.87 126.30%	Perf 3Y	131.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.61% 59.21%	Gross Margin	83.64%	Volatility	3.36% 2.76%	Perf 5Y	272.15%
Dividend TTM	-	EV/Sales	24.76	EPS Y/Y TTM	-330.09%	Oper. Margin	-7.32%	ATR (14)	13.20	Perf 10Y	358.46%
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	5.01%	Profit Margin	-12.96%	RSI (14)	64.85	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	2.80	EPS Q/Q	-280.65%	SMA20	2.02%	Beta	0.36	Target Price	457.28
Payout	-	Debt/Eq	10.93	Sales Q/Q	17.26%	SMA50	16.72%	Rel Volume	0.57	Prev Close	468.58
Employees	2230	LT Debt/Eq	10.36	Earnings	Jul 31 BMO	SMA200	56.30%	Avg Volume	1.12M	Price	465.89
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.20% 16.72%	Trades		Volume	630,774	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform	$490
Jul-30-25	Resumed	Raymond James	Outperform	$370
Jul-21-25	Initiated	Truist	Buy	$385
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222

Show Previous Ratings

Sep-10-25 12:16PM	Top 20 biopharma market caps fall 5.7% amid industry challenges (Pharmaceutical Technology)
06:42AM	Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Sep-09-25 11:16PM	Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes (Business Wire) +5.96%
Sep-08-25 04:15PM	Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes (Business Wire)
10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
11:25AM	Loading…
Sep-04-25 11:25AM	Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock? (Zacks)
Sep-02-25 09:33AM	Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio? (Insider Monkey)
07:07AM	Alnylam reports new analysis from trial of Amvuttra for ATTR-CM (Clinical Trials Arena)
02:30AM	Startup Corsera Health aims to bring preventive heart medicine to the masses (BioPharma Dive)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
05:15AM	New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM (Business Wire)
Aug-30-25 10:30AM	Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension (Business Wire)
10:30AM	Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial (Business Wire)
Aug-28-25 10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
09:50AM	Loading…
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-27-25 08:00AM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire)
Aug-15-25 10:46AM	Private Credit Is a Booming Business. Where One Pro Sees Risks and Opportunities Now. (Barrons.com)
Aug-11-25 10:30AM	Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock (Barchart)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
08:00AM	Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 (Business Wire)
Aug-06-25 03:27PM	RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment. (Barrons.com)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
Aug-05-25 08:00AM	Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-04-25 07:48PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:20PM	Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? (Zacks)
09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Aug-01-25 07:31PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
02:28PM	Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance (Benzinga)
11:49AM	Loading…
11:49AM	ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up (Zacks)
Jul-31-25 10:30AM	Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +15.43%
10:17AM	Alnylam reaches new highs on strong sales of closely watched rare disease drug (BioPharma Dive)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:18AM	Alnylam: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Jul-25-25 10:43PM	Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA (Insider Monkey)
10:00AM	Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-24-25 10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-22-25 12:00PM	Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jul-17-25 08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results (Business Wire)
Jul-02-25 12:30PM	OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients (PR Newswire)
Jun-29-25 09:50PM	BMO Capital Maintains 'Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT (Insider Monkey)
Jun-19-25 10:10AM	Alnylam names Pushkal Garg as EVP, chief research and development officer (TipRanks)
Jun-18-25 10:05AM	Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer (Business Wire)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-11-25 07:31PM	The European Commission Approves Alnylam's AMVUTTRA (Insider Monkey)
07:00AM	Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
05:21AM	EC approves Alnylams vutrisiran for ATTR-CM treatment (Pharmaceutical Technology)
Jun-09-25 06:00AM	Alnylam Receives European Commission Approval for AMVUTTRA (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Jun-05-25 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report? (Zacks)
06:20AM	Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar? (Zacks)
May-28-25 08:00AM	Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-20-25 09:00AM	Alnylam Issues 2024 Corporate Responsibility Report (Business Wire)
May-19-25 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
May-17-25 05:50AM	AMVUTTRA (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B (Business Wire)
May-13-25 10:18PM	Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-12-25 07:00AM	Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress (Business Wire) +7.58%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -6.58%
04:00AM	Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications (Pharma Voice)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 07:17PM	Tracking Baillie Gifford's 13F Portfolio - Q1 2025 Update (Seeking Alpha)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
May-05-25 10:00AM	Fidelity OTC Portfolio Q1 2025 Commentary (Seeking Alpha) +5.46%
10:00AM	Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference (Business Wire)
May-02-25 10:51AM	Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y (Zacks)
03:05AM	Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:29AM	Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 10:46PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
01:11PM	Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:20AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:22AM	Alnylam: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Apr-30-25 08:02PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
05:15PM	MiMedx (MDXG) Q1 Earnings Match Estimates (Zacks)
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
Apr-29-25 04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
09:15AM	Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
08:00AM	Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Apr-24-25 10:01AM	Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results (Business Wire)
Apr-14-25 02:03PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +5.08%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks) -6.98%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 02:08PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-04-25 08:04PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -10.08%
04:54PM	Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor (Zacks)
Apr-02-25 06:20AM	Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar? (Zacks)
Apr-01-25 09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks) -5.28%
08:00AM	Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-29-25 01:00PM	Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 (Business Wire)
Mar-28-25 04:44PM	FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reitan Colleen F	Director	Sep 09 '25	Option Exercise	100.65	18,000	1,811,700	18,775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Sale	467.60	18,000	8,416,730	775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Proposed Sale	461.12	18,000	8,300,070		Sep 09 04:05 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 29 '25	Sale	448.37	3,474	1,557,649	25,992	Sep 02 04:10 PM
Tanguler Tolga	Officer	Aug 29 '25	Proposed Sale	452.22	3,474	1,571,012		Aug 29 04:05 PM
Garg Pushkal	EVP Chief R&D	Aug 19 '25	Sale	458.41	1,455	666,987	20,221	Aug 19 05:28 PM
Garg Pushkal	EVP Chief R&D	Aug 18 '25	Sale	453.27	1,396	632,759	21,676	Aug 19 05:28 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 18 '25	Sale	453.27	1,396	632,759	29,466	Aug 19 05:28 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 18 '25	Sale	453.27	2,274	1,030,727	50,121	Aug 19 05:27 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 18 '25	Sale	453.27	6,979	3,163,346	56,221	Aug 19 05:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 18 '25	Sale	453.27	1,396	632,759	22,719	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Option Exercise	70.20	11,250	789,750	28,054	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Sale	450.00	11,250	5,062,500	16,804	Aug 19 05:26 PM
Garg Pushkal	Officer	Aug 19 '25	Proposed Sale	457.00	1,455	664,935		Aug 19 04:03 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Proposed Sale	450.00	11,250	5,062,500		Aug 18 04:08 PM
Ausiello Dennis A	Director	Aug 14 '25	Option Exercise	131.34	31,448	4,130,478	32,359	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Sale	436.58	31,448	13,729,536	911	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Proposed Sale	433.59	31,448	13,635,538		Aug 14 04:17 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Option Exercise	118.46	31,640	3,748,149	80,588	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Option Exercise	118.73	19,297	2,291,057	68,245	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Sale	304.39	31,640	9,630,902	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Sale	306.00	19,297	5,904,882	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Officer	Jun 02 '25	Proposed Sale	303.10	19,297	5,848,824		Jun 02 04:08 PM
Greenstreet Yvonne	Officer	May 30 '25	Proposed Sale	304.39	31,640	9,630,902		May 30 04:18 PM
SHARP PHILLIP A	Director	May 30 '25	Proposed Sale	300.00	11,250	3,375,000		May 30 04:10 PM
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Oct 17 '24	Buy	302.67	4	1,211	36	May 12 04:05 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Option Exercise	42.22	5,445	229,888	25,666	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Sale	300.00	5,445	1,633,500	20,221	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 21 '25	Sale	285.00	4,321	1,231,485	20,221	Mar 25 04:10 PM
PYOTT DAVID E I	Director	Mar 24 '25	Option Exercise	88.95	7,440	661,788	7,576	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Sale	299.00	7,440	2,224,560	136	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Proposed Sale	299.00	7,440	2,224,560		Mar 24 04:13 PM
Garg Pushkal	Officer	Mar 24 '25	Proposed Sale	300.00	5,445	1,633,500		Mar 24 04:06 PM
Garg Pushkal	Officer	Mar 21 '25	Proposed Sale	285.00	4,321	1,231,485		Mar 21 04:03 PM
SCHULMAN AMY W	Director	Mar 13 '25	Option Exercise	131.21	2,750	360,828	11,186	Mar 14 04:16 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 14 '25	Sale	255.17	1,213	309,527	81,526	Feb 18 04:49 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 14 '25	Sale	255.17	967	246,750	32,786	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 18 '25	Sale	251.56	1,440	362,243	12,881	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 14 '25	Sale	255.21	663	169,204	14,321	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 14 '25	Sale	255.17	1,561	398,325	13,537	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 18 '25	Sale	251.67	1,548	389,579	11,989	Feb 18 04:47 PM
Garg Pushkal	Officer	Feb 18 '25	Proposed Sale	256.95	1,548	397,759		Feb 18 04:14 PM
Fitzgerald Kevin Joseph	Officer	Feb 18 '25	Proposed Sale	256.95	1,440	370,008		Feb 18 04:13 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Option Exercise	88.95	48,876	4,347,520	64,581	Jan 29 04:03 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Sale	285.00	52,592	14,988,720	11,989	Jan 29 04:03 PM
Garg Pushkal	Officer	Jan 27 '25	Proposed Sale	285.00	52,592	14,988,720		Jan 27 04:01 PM
SHARP PHILLIP A	Director	Jan 23 '25	Option Exercise	131.21	11,250	1,476,112	11,250	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Sale	275.00	11,250	3,093,750	0	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Proposed Sale	275.00	11,250	3,093,750		Jan 23 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Dec 12 '24	Sale	251.00	1,752	439,760	15,705	Dec 13 04:13 PM
Garg Pushkal	Officer	Dec 12 '24	Proposed Sale	255.02	1,752	446,795		Dec 12 04:05 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '24	Sale	250.98	5,219	1,309,853	78,880	Nov 27 05:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Nov 26 '24	Sale	250.98	1,682	422,144	17,457	Nov 27 05:22 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Nov 26 '24	Sale	250.98	1,682	422,144	30,644	Nov 27 05:21 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Nov 26 '24	Sale	250.98	1,469	368,686	13,191	Nov 27 05:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 27 '24	Sale	252.29	1,531	386,261	12,881	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 26 '24	Sale	250.98	1,469	368,686	14,412	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	Officer	Nov 27 '24	Proposed Sale	253.98	1,531	388,843		Nov 27 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience